On August 13, Liquidia Technologies Inc fell 5.12% in regular trading, trading at $83.15/share, with turnover of approximately $140 million. The decline followed the company's Q2 earnings release on August 12, where EPS slightly missed certain analyst expectations, prompting profit-taking after a strong prior rally.

Liquidia reported Q2 EPS of $0.74, swinging from a loss of $0.49 per share a year earlier. While revenue of $171.7 million vastly exceeded the $8.8 million reported a year ago and beat the consensus estimate of $168.5 million, EPS fell short of the FactSet estimate of $0.76. Core product YUTREPIA achieved net sales of approximately $170.4 million, up 31% sequentially, with approximately 5,900 unique patient prescriptions. Despite the dramatic revenue growth and profitability turnaround, the stock had already reflected high-growth expectations heading into the report, and the slight EPS miss triggered selling pressure.

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing products for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, headquartered in Morrisville, North Carolina.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)